Colton McCoy, MD
Cornea and External Diseases Specialist · Atlanta, GANPI 1407316995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Dompe US, Inc. at 28.8% of the total.
Across 13 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$159
- Bausch & Lomb Americas Inc.$147
- Alcon$110
- Rxsight Inc$65
- Dutch Ophthalmic, USA$25
- Ocular Therapeutix, Inc.$24
- plus $22 from 1 others
What the payments were for
- Food & beverage$553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 2 | $159 |
| Bausch & Lomb Americas Inc. | 1 | $147 |
| Alcon | 5 | $110 |
| Rxsight Inc | 2 | $65 |
| Dutch Ophthalmic, USA | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IC-8 Apthera IOL$147
- enVista MX60 IOL$147
- Oxervate$138
How this compares
Too few cornea and external diseases specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $14,097 |
| Prednisolone Acetate | 82 | $3,134 |
| MoxifloxacinMoxifloxacin Hcl | 65 | $2,697 |
| ValacyclovirValacyclovir Hcl | 14 | $472 |
| Ketorolac Tromethamine | 20 | $431 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $244 |
| Latanoprost | 13 | $100 |
| ErythromycinErythromycin Base | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Other cornea and external diseases specialist in Atlanta
- William LeeAtlanta$501K
- Joseph ChristenburyAtlanta$31K
- Soroosh BehshadAtlanta$7K
- Evan LoftAtlanta$2K
- Amit BajajAtlanta$1K
- Amy EstesAugusta$2K
- Abigail KalishMarietta$1K
- Barbara SmithMarietta$633
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.